Literature DB >> 18759749

Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18.

Laila Darwich1, Gemma Coma, Ruth Peña, Rocio Bellido, Ester J J Blanco, José A Este, Francesc E Borras, Bonaventura Clotet, Lidia Ruiz, Antoni Rosell, Felipe Andreo, R Michael E Parkhouse, Margarita Bofill.   

Abstract

The interferon (IFN)-gamma component of the immune response plays an essential role in combating infectious and non-infectious diseases. Induction of IFN-gamma secretion by human T and natural killer (NK) cells through synergistic costimulation with interleukin (IL)-12 and IL-18 in the adaptive immune responses against pathogens is well established, but induction of similar activity in macrophages is still controversial, with doubts largely focusing on contamination of macrophages with NK or T cells in the relevant experiments. The possible contribution of macrophages to the IFN response is, however, an important factor relevant to the pathogenesis of many diseases. To resolve this issue, we analysed the production of IFN-gamma at the single-cell level by immunohistochemistry and by enzyme-linked immunosorbent spot (ELISPOT) analysis and unequivocally demonstrated that human macrophages derived from monocytes in vitro through stimulation with a combination of IL-12 and IL-18 or with macrophage colony-stimulating factor (M-CSF) were able to produce IFN-gamma when further stimulated with a combination of IL-12 and IL-18. In addition, naturally activated alveolar macrophages immediately secreted IFN-gamma upon treatment with IL-12 and IL-18. Therefore, human macrophages in addition to lymphoid cells contribute to the IFN-gamma response, providing another link between the innate and acquired immune responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18759749      PMCID: PMC2669819          DOI: 10.1111/j.1365-2567.2008.02905.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

1.  The production of IFN-gamma by IL-12/IL-18-activated macrophages requires STAT4 signaling and is inhibited by IL-4.

Authors:  H Schindler; M B Lutz; M Röllinghoff; C Bogdan
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

2.  IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells.

Authors:  K Tominaga; T Yoshimoto; K Torigoe; M Kurimoto; K Matsui; T Hada; H Okamura; K Nakanishi
Journal:  Int Immunol       Date:  2000-02       Impact factor: 4.823

Review 3.  Interferon-gamma and interleukin-12 pathway defects and human disease.

Authors:  S E Dorman; S M Holland
Journal:  Cytokine Growth Factor Rev       Date:  2000-12       Impact factor: 7.638

Review 4.  IFN-gamma production by antigen-presenting cells: mechanisms emerge.

Authors:  D M Frucht; T Fukao; C Bogdan; H Schindler; J J O'Shea; S Koyasu
Journal:  Trends Immunol       Date:  2001-10       Impact factor: 16.687

5.  Treatment of monocytes with interleukin (IL)-12 plus IL-18 stimulates survival, differentiation and the production of CXC chemokine ligands (CXCL)8, CXCL9 and CXCL10.

Authors:  G Coma; R Peña; J Blanco; A Rosell; F E Borras; J A Esté; B Clotet; L Ruiz; R M E Parkhouse; M Bofill
Journal:  Clin Exp Immunol       Date:  2006-09       Impact factor: 4.330

6.  Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18 and interleukin-12 on human monocytes.

Authors:  Rogier J L Stuyt; Mihai G Netea; Teunis B H Geijtenbeek; Bart Jan Kullberg; Charles A Dinarello; Jos W M van der Meer
Journal:  Immunology       Date:  2003-11       Impact factor: 7.397

7.  Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis.

Authors:  B W Robinson; T L McLemore; R G Crystal
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

8.  Regulation of cell-surface receptors for human interferon-gamma on the human histiocytic lymphoma cell line U937.

Authors:  D S Finbloom
Journal:  Biochem J       Date:  1991-03-15       Impact factor: 3.857

Review 9.  Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection.

Authors:  JoAnn M Tufariello; John Chan; JoAnne L Flynn
Journal:  Lancet Infect Dis       Date:  2003-09       Impact factor: 25.071

10.  Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis.

Authors:  Norbert Gerdes; Galina K Sukhova; Peter Libby; Rebecca S Reynolds; James L Young; Uwe Schönbeck
Journal:  J Exp Med       Date:  2002-01-21       Impact factor: 14.307

View more
  84 in total

1.  Acute and neuropathic orofacial antinociceptive effect of eucalyptol.

Authors:  José de Maria de Albuquerque de Melo Júnior; Marina de Barros Mamede Vidal Damasceno; Sacha Aubrey Alves Rodrigues Santos; Talita Matias Barbosa; João Ronielly Campêlo Araújo; Antonio Eufrásio Vieira-Neto; Deysi Viviana Tenazoa Wong; Roberto César Pereira Lima-Júnior; Adriana Rolim Campos
Journal:  Inflammopharmacology       Date:  2017-02-16       Impact factor: 4.473

2.  Toxoplasma gondii cyclophilin 18-mediated production of nitric oxide induces Bradyzoite conversion in a CCR5-dependent manner.

Authors:  Hany M Ibrahim; Hiroshi Bannai; Xuenan Xuan; Yoshifumi Nishikawa
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

3.  Depot-specific differences in inflammatory mediators and a role for NK cells and IFN-gamma in inflammation in human adipose tissue.

Authors:  R W O'Rourke; M D Metcalf; A E White; A Madala; B R Winters; I I Maizlin; B A Jobe; C T Roberts; M K Slifka; D L Marks
Journal:  Int J Obes (Lond)       Date:  2009-06-30       Impact factor: 5.095

4.  Inhibition of Necroptosis to Prevent Long-term Cardiac Damage During Pneumococcal Pneumonia and Invasive Disease.

Authors:  Sarah M Beno; Ashleigh N Riegler; Ryan P Gilley; Terry Brissac; Yong Wang; Katherine L Kruckow; Jeevan K Jadapalli; Griffin M Wright; Anukul T Shenoy; Sara N Stoner; Marcos I Restrepo; Jessy S Deshane; Ganesh V Halade; Norberto González-Juarbe; Carlos J Orihuela
Journal:  J Infect Dis       Date:  2020-11-09       Impact factor: 5.226

5.  Natural History and Pathogenesis of Wild-Type Marburg Virus Infection in STAT2 Knockout Hamsters.

Authors:  Colm Atkins; Jinxin Miao; Birte Kalveram; Terry Juelich; Jennifer K Smith; David Perez; Lihong Zhang; Jonna L B Westover; Arnaud J Van Wettere; Brian B Gowen; Zhongde Wang; Alexander N Freiberg
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

6.  The impact of alcohol use disorders on pulmonary immune cell inflammatory responses to Streptococcus pneumoniae.

Authors:  Jeanette Gaydos; Alicia McNally; Ellen L Burnham
Journal:  Alcohol       Date:  2018-09-05       Impact factor: 2.405

Review 7.  Shared signaling systems in myeloid cell-mediated muscle regeneration.

Authors:  James G Tidball; Kenneth Dorshkind; Michelle Wehling-Henricks
Journal:  Development       Date:  2014-03       Impact factor: 6.868

8.  In vitro effects of azide-containing human CRP isoforms and oxLDL on U937-derived macrophage production of atherosclerosis-related cytokines.

Authors:  Dania Jundi; Imtissal Krayem; Samer Bazzi; Marc Karam
Journal:  Exp Ther Med       Date:  2020-09-04       Impact factor: 2.447

9.  Discrete Dynamical Modeling of Influenza Virus Infection Suggests Age-Dependent Differences in Immunity.

Authors:  Ericka Keef; Li Ang Zhang; David Swigon; Alisa Urbano; G Bard Ermentrout; Michael Matuszewski; Franklin R Toapanta; Ted M Ross; Robert S Parker; Gilles Clermont
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

10.  Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile.

Authors:  Julian Maggini; Gerardo Mirkin; Ianina Bognanni; Josefina Holmberg; Isabel M Piazzón; Irene Nepomnaschy; Héctor Costa; Cristian Cañones; Silvina Raiden; Mónica Vermeulen; Jorge R Geffner
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.